High investments in research and development

Collaboration with scientists and researchers is decisive for the scientific approach of Geistlich. In the company’s own research and development department, top-qualified scientists and researchers work on the further development of biomaterials. Compared with the overall number of employees, the company has an exceptionally large research and development department and is continuously making high investments in state-of-the-art technology and equipment. Another focus of the company is on the intensive exchange with universities around the globe.


Diverse research area

The research covers various areas: From cell biology, biochemistry, material research to research analytics and ultimately process development, all relevant areas are covered that are important in the regeneration of bone and tissue. The task of research is to develop biological matrix structures.

"We are continuously investing in our research.”
Dr. Terance Hart, CSO Geistlich Pharma

The goal is to achieve an optimum interaction between material and body – for the regeneration of natural tissue. Geistlich sets itself the requirement of having developed a deep understanding for biological characteristics of matrix structures. Since its beginnings in 1851, the company has dealt with the processing and refining of bone and collagen materials. The company also aims to manufacture ideal products for practical and general use and to support them with first-class scientific data.


Hundreds of studies document efficacy

Up to now, there have been more than 900 scientific publications on Geistlich biomaterials. All new Geistlich Pharma developments are tested until they meet the company’s rigorous standards with regard to quality, safety and efficacy in full. It is important for Geistlich Pharma AG to understand the clinical needs of the experts so that they can treat their patients correctly. For this, the company can draw on a wide network of international experts. With practitioners and leading opinion leaders, Geistlich Pharma AG develops new products and treatment concepts and continuously invests in studies.


Focus on a scientific approach

The company was defined by its scientific approach and partnerships with universities right from the outset. With international researchers – primarily with Prof. Dr. Philip J. Boyne from the University of Loma Linda in California - Dr. Peter Geistlich did pioneering work in the field of bone regeneration and developed the bone replacement material Geistlich Bio-Oss® and the collagen membrane Geistlich Bio-Gide®. Geistlich Pharma AG is dedicated to the approach of science-based development and to continue its intensive scientific research and high investments in this field.


Dr. Mirjam Kessler
Director Corporate Communications